MyFinsight
Home
Compare
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Free Cash flow
-$25,498K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Change in fair value of warrant ...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Interest amortization on marketa...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Segment expenses
-
-
695,981
-
Net loss
-62,807
-219,585
1,722,858
-812,684
Depreciation expense
36
28
23
2
Non-cash lease expense
109
109
107
60
Stock-based compensation
9,399
8,870
7,106
8,029
Transaction costs for issuance of pre-funded warrants
-
-
0
643
Change in fair value of warrant liabilities
19,297
188,360
-1,756,021
2,090,379
Interest amortization on marketable securities
425
488
34
11
Loss on sale of property and equipment
0
0
0
0
Issuance of pre-funded warrants in connection with the acquisition of in-process research and development
-
-
0
177,377
Acquisition of in-process research and development
0
-
-
-
Operating lease liabilities, net
-62
-61
-59
-20
Prepaid expenses and other current assets
-278
6,359
873
75
Accounts payable, accrued liabilities and other current liabilities
8,804
-9,100
6,206
5,001
Other assets
7
20
2,114
-151
Net cash used in operating activities
-25,378
-38,246
-22,801
-53,662
Purchases of marketable securities
79,000
276,500
53,660
0
Proceeds from maturities of marketable securities
42,586
13,311
5,000
0
Purchases of property and equipment
120
48
314
244
Proceeds from sales of property and equipment
0
-
0
0
Net cash (used in) provided by investing activities
-36,534
-263,237
-48,974
-244
Proceeds from the issuance of common stock from underwritten public offering, net of underwriting discount and commissions
-
-
108,101
-
Payment of issuance costs related to private placements
107
-1,067
-
643
Proceeds from the issuance of pre-funded warrants
0
-
0
0
Payment of issuance costs related to underwritten public offering and private placements
-
-
1,325
-
Proceeds from exercise of pre-funded warrants
3
-
-
-
Proceeds from the issuance of common stock from at-the-market sales agreement, net of issuance costs
-
-
49,849
20,257
Proceeds from stock option exercises and the issuance of shares under espp
0
-
129
1,954
Repurchases of shares for tax withholdings upon vesting of restricted stock unit awards
2
2
148
19
Proceeds from issuance of common stock in private placement
0
74,999
149,999
-
Net cash provided by financing activities
-106
74,870
307,799
21,549
Net (decrease) increase in cash, cash equivalents and restricted cash equivalents
-62,018
-226,613
236,024
-32,357
Cash, cash equivalents and restricted cash equivalents, beginning of period
170,041
396,654
160,630
84,362
Cash, cash equivalents and restricted cash equivalents, end of period
108,023
-
-
-
Purchases of property and equipment in accounts payable and accrued liabilities
12
-
-
-
Unrealized loss on available-for-sale securities
-964
-
-
-
Unpaid license payments included in accounts payable and accrued expenses
0
-
-
-
Issuance costs associated with the sale of pre-funded warrants included in accounts payable and accrued expenses
0
-
-
-
Cash and cash equivalents
107,855
-
-
-
Restricted cash equivalents
168
-
-
-
Total cash, cash equivalents and restricted cash equivalents as shown on the statements of cash flows
108,023
170,041
396,654
160,630
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net (decrease)
increase in cash, cash...
-$62,018K
(-157.09%↓ Y/Y)
Proceeds from maturities
of marketable...
$42,586K
Change in fair value of
warrant liabilities
$19,297K
Stock-based compensation
$9,399K
(148.85%↑ Y/Y)
Accounts payable,
accrued liabilities and...
$8,804K
(3278.34%↑ Y/Y)
Prepaid expenses and
other current assets
-$278K
(89.44%↑ Y/Y)
Non-cash lease expense
$109K
(-98.01%↓ Y/Y)
Depreciation expense
$36K
(-98.74%↓ Y/Y)
Proceeds from exercise of
pre-funded warrants
$3K
Net cash (used in)
provided by investing...
-$36,534K
(-8882.21%↓ Y/Y)
Net cash used in
operating activities
-$25,378K
(61.69%↑ Y/Y)
Net cash provided by
financing activities
-$106K
(-100.06%↓ Y/Y)
Canceled cashflow
$42,586K
Canceled cashflow
$37,923K
Canceled cashflow
$3K
Purchases of marketable
securities
$79,000K
Net loss
-$62,807K
(96.09%↑ Y/Y)
Payment of issuance
costs related to...
$107K
(-80.58%↓ Y/Y)
Purchases of property and
equipment
$120K
(-68.67%↓ Y/Y)
Interest amortization on
marketable securities
$425K
(1831.82%↑ Y/Y)
Operating lease
liabilities, net
-$62K
(97.34%↑ Y/Y)
Other assets
$7K
(100.36%↑ Y/Y)
Repurchases of shares for tax
withholdings upon vesting of...
$2K
(-97.70%↓ Y/Y)
Buy us a coffee
Vor Biopharma Inc. (VOR)
Vor Biopharma Inc. (VOR)